157 related articles for article (PubMed ID: 21094046)
21. Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5alpha-reductase.
McNulty AM; Audia JE; Bemis KG; Goode RL; Rocco VP; Neubauer BL
J Steroid Biochem Mol Biol; 2000; 72(1-2):13-21. PubMed ID: 10731633
[TBL] [Abstract][Full Text] [Related]
22. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
23. Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride.
Xiao Q; Wang L; Supekar S; Shen T; Liu H; Ye F; Huang J; Fan H; Wei Z; Zhang C
Nat Commun; 2020 Oct; 11(1):5430. PubMed ID: 33110062
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
25. Re: 5α-Reductase Type 1 Modulates Insulin Sensitivity in Men.
Kaplan SA
J Urol; 2015 Sep; 194(3):736-7. PubMed ID: 26292878
[No Abstract] [Full Text] [Related]
26. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition.
Azzolina B; Ellsworth K; Andersson S; Geissler W; Bull HG; Harris GS
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):55-64. PubMed ID: 9328210
[TBL] [Abstract][Full Text] [Related]
28. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2.
Levy MA; Brandt M; Sheedy KM; Dinh JT; Holt DA; Garrison LM; Bergsma DJ; Metcalf BW
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):197-206. PubMed ID: 8142295
[TBL] [Abstract][Full Text] [Related]
29. Quintaquinone, a Merosesquiterpene from the Yellow Sponge
Jiso A; Kittiwisut S; Chantakul R; Yuenyongsawad S; Putchakarn S; Schäberle TF; Temkitthaworn P; Ingkaninan K; Chaithirayanon K; Plubrukarn A
J Nat Prod; 2020 Feb; 83(2):532-536. PubMed ID: 32040314
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of 5α-reductase inhibitory activity of certain herbs useful as antiandrogens.
Nahata A; Dixit VK
Andrologia; 2014 Aug; 46(6):592-601. PubMed ID: 23710567
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
Aggarwal S; Thareja S; Bhardwaj TR; Haupenthal J; Hartmann RW; Kumar M
Eur J Med Chem; 2012 Aug; 54():728-39. PubMed ID: 22776417
[TBL] [Abstract][Full Text] [Related]
32. Mechanism based representation of the active site of 5 alpha-reductase (5AR).
Ahmed S; Denison S
Bioorg Med Chem Lett; 1998 Sep; 8(18):2615-70. PubMed ID: 9873591
[TBL] [Abstract][Full Text] [Related]
33. Finasteride.
Chaudhary UB; Turner JS
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):873-81. PubMed ID: 20536414
[TBL] [Abstract][Full Text] [Related]
34. [Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats].
Wang XD; Jia Y; Cui YG; Wang XH; Tong JS; Ma DZ; Cai RF; Di FS
Zhonghua Nan Ke Xue; 2005 Sep; 11(9):652-4. PubMed ID: 16209201
[TBL] [Abstract][Full Text] [Related]
35. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
36. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.
Makridakis NM; di Salle E; Reichardt JK
Pharmacogenetics; 2000 Jul; 10(5):407-13. PubMed ID: 10898110
[TBL] [Abstract][Full Text] [Related]
38. Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids.
Thareja S; Rajpoot T; Verma SK
Steroids; 2015 Mar; 95():96-103. PubMed ID: 25582615
[TBL] [Abstract][Full Text] [Related]
39. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
40. Role of 5α-dihydrotestosterone in testicular development of gilthead seabream following finasteride administration.
García-García M; Sánchez-Hernández M; García-Hernández MP; García-Ayala A; Chaves-Pozo E
J Steroid Biochem Mol Biol; 2017 Nov; 174():48-55. PubMed ID: 28739284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
